Withdrawn before start: experimental cocktail for type 1 diabetes never tested

NCT ID NCT02586831

Terminated Disease control Sponsor: Camillo Ricordi and Jay Skyler Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aimed to test whether a combination of four drugs—ATG, low-dose IL-2, adalimumab, and exenatide—could help people newly diagnosed with type 1 diabetes keep producing their own insulin. The trial planned to enroll adults aged 18-35 diagnosed within the last 120 days. However, the study was withdrawn before any participants were enrolled, so no data is available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-Thymocyte Globulin (ATG), low-dose Interleukin-2 (IL-2), adalimumab, and exenatide
What this could lead to: If successful, this combination could help people with new-onset type 1 diabetes keep making their own insulin longer, reducing the need for injected insulin.
What could go wrong: This trial was withdrawn before enrolling anyone, so no results are available. The combination of multiple immune-suppressing drugs carries risks of infection and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease diabetes mellitus hypoglycemia type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES DIABETES MELLITUS DIABETES MELLITUS, TYPE 1 HYPOGLYCEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.